Abstract
A patient with AML (FAB M4Eo) developed EBV-LPD 1.5 months after allogeneic BMT from his one locus-mismatched mother, the diagnosis being confirmed on day +82. Attempts to eradicate the monoclonally proliferating LPD using chemotherapy (VP16/dexa- methasone) followed by two doses of EBV-specific CTL and one dose of unstimulated donor leukocytes were not successful. We assume delay of infusions (day +100, +107) and insufficient CTL cell doses (total 9.2 × 106) may have been responsible for the poor outcome in this case.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Imashuku, S., Goto, T., Matsumura, T. et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 20, 337–340 (1997). https://doi.org/10.1038/sj.bmt.1700883
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700883
Keywords
This article is cited by
-
Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT
Bone Marrow Transplantation (2018)
-
Virus-Specific T Cells for Hematopoietic Stem Cell Transplantation
Current Stem Cell Reports (2017)
-
T-cell therapy in the treatment of post-transplant lymphoproliferative disease
Nature Reviews Clinical Oncology (2012)
-
Immunotherapy for EBV-associated malignancies
International Journal of Hematology (2011)
-
Adoptive cellular immunotherapy for viral diseases
Bone Marrow Transplantation (2008)